No Abstract BioWorld International CorrespondentPARIS - Genomic Vision, which is developing new diagnostic tools and therapeutics in the areas of cancer and acute genetic and viral diseases, completed a series B financing in which it raised €4 million (US$6.3 million). Read More
LONDON - TauRx Therapeutics Ltd. presented positive data on the first tau inhibitor to complete Phase II in the treatment of Alzheimer's disease, showing the drug, rember, slowed the progress of the mild to moderate form of the disorder by 81 percent over 12 months. (BioWorld International) Read More
